Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer

Clinical Cancer Research

Volumn 22, Issue 12, 2016, Pages 3005-3015

  Kroeger, David R ^a   Milne, Katy ^a   Nelson, Brad H ^a,b,c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF VICTORIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CANCER TESTIS ANTIGEN; CD20 ANTIGEN; B CELL MATURATION ANTIGEN; CANCER ANTIBODY; IMMUNOGLOBULIN G; TNFRSF17 PROTEIN, HUMAN;

ARTICLE; B LYMPHOCYTE; CANCER GRADING; CANCER PROGNOSIS; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; LYMPHOCYTE SUBPOPULATION; OVARY CANCER; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; SOLID TUMOR; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; ADULT; AGED; BIOSYNTHESIS; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PROCEDURES; PROGNOSIS; TERTIARY LYMPHOID STRUCTURE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEOPLASM; B-CELL MATURATION ANTIGEN; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; OVARIAN NEOPLASMS; PLASMA CELLS; PROGNOSIS; T-LYMPHOCYTES, CYTOTOXIC; TERTIARY LYMPHOID STRUCTURES;

EID: 84964567438     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2762     Document Type: Article

References (50)

1. Tabassum DP, Polyak K. Tumorigenesis: it takes a village. Nat Rev Cancer 2015;15:473-83.
2. Pribluda A, de la Cruz CC, Jackson EL. Intratumoral heterogeneity: from diversity comes resistance. Clin Cancer Res 2015;21:2916-23.
3. Bowtell DD, Bohm S, Ahmed AA, Aspuria PJ, Bast RCJr, Beral V, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer 2015;15:668-79.
4. The Cancer Genome Atlas Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
5. Bashashati A, Ha G, Tone A, Ding J, Prentice LM, Roth A, et al.Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol 2013;231:21-34.
6. Schwarz RF, Ng CK, Cooke SL, Newman S, Temple J, Piskorz AM, et al. Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. PLoS Med 2015;12:e1001789.
7. Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, et al.Whole-genome characterization of chemoresistant ovarian cancer. Nature 2015;521:489-94.
8. Castellarin M, Milne K, Zeng T, Tse K, Mayo M, Zhao Y, et al.Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease. J Pathol 2013;229:515-24.
9. Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol 2012;124:192-8.
10. Milne K, Kobel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, et al.Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One 2009;4:e6412.
11. Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH, et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotypeand together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res 2012;18:3281-92.
12. Richards CH, Flegg KM, Roxburgh CS, Going JJ, Mohammed Z, Horgan PG, et al.The relationships between cellular components of the peritumoural inflammatory response, clinicopathological characteristics and survival in patients with primary operable colorectal cancer. Br J Cancer 2012;106:2010-5.
13. Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, et al.A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin kappa C as a compatible prognostic marker in human solid tumors. Clin Cancer Res 2012;18:2695-703.
14. Iglesia MD, Vincent BG, Parker JS, Hoadley KA, Carey LA, Perou CM, et al.Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clin Cancer Res 2014;20:3818-29.
15. Yanni G, Whelan A, Feighery C, Bresnihan B. Analysis of cell populations in rheumatoid arthritis synovial tissues. Semin Arthritis Rheum 1992;21:393-9.
16. Pitzalis C, Jones GW, Bombardieri M, Jones SA. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat Rev Immunol 2014;14:447-62.
17. Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, et al.Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008;26:4410-7.
18. Martinet L, Garrido I, Filleron T, Le Guellec S, Bellard E, Fournie JJ, et al. Human solid tumors contain high endothelial venules: association with T-and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res 2011;71:5678-87.
19. Coppola D, Nebozhyn M, Khalil F, Dai H, Yeatman T, Loboda A, et al. Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am J Pathol 2011;179:37-45.
20. Clarke B, Tinker AV, Lee CH, Subramanian S, van de Rijn M, Turbin D, et al.Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol 2009;22:393-402.
21. Lohr M, Edlund K, Botling J, Hammad S, Hellwig B, Othman A, et al.The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer. Cancer Lett 2013;333:222-8.
22. Rangel-Moreno J, Moyron-Quiroz JE, Carragher DM, Kusser K, Hartson L, Moquin A, et al.Omental milky spots develop in the absence of lymphoid tissue-inducer cells and support B and T cell responses to peritoneal antigens. Immunity 2009;30:731-43.
23. deLeeuw RJ, Kroeger DR, Kost SE, Chang PP, Webb JR, Nelson BH. CD25 Identifies a Subset of CD4+FoxP3-TIL That Are Exhausted Yet Prognostically Favorable in Human Ovarian Cancer. Cancer Immunol Res 2015;3:245-53.
24. Darce JR, Arendt BK, Wu X, Jelinek DF. Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol 2007;179:7276-86.
25. O'Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, et al.BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004;199:91-8.
26. Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al.The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 2015;21:938-45.
27. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al.The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401-4.
28. Kunkel EJ, Butcher EC. Plasma-cell homing. Nat Rev Immunol 2003;3:822-9.
29. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015;348:69-74.
30. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al.Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008;14:5198-208.
31. George J, Alsop K, Etemadmoghadam D, Hondow H, Mikeska T, Dobrovic A, et al.Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. Clin Cancer Res 2013;19:3474-84.
32. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al.Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013;39:782-95.
33. Qin Z, Richter G, Schuler T, Ibe S, Cao X, Blankenstein T. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 1998;4:627-30.
34. Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, Wejksza K, et al.Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4(+) T cells to T-regulatory cells. Cancer Res 2011;71:3505-15.
35. Fillatreau S.Regulatory plasma cells. Curr Opin Pharmacol 2015;23:1-5.
36. Shalapour S, Font-Burgada J, Di Caro G, Zhong Z, Sanchez-Lopez E, Dhar D, et al.Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature 2015;521:94-8.
37. Muehlinghaus G, Cigliano L, Huehn S, Peddinghaus A, Leyendeckers H, Hauser AE, et al.Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. Blood 2005;105:3965-71.
38. Lacotte S, Decossas M, Le Coz C, Brun S, Muller S, Dumortier H. Early differentiated CD138(high) MHCII+ IgG+ plasma cells express CXCR3 and localize into inflamed kidneys of lupus mice. PLoS One 2013;8:e58140.
39. Chihara N, Aranami T, Oki S, Matsuoka T, Nakamura M, Kishida H, et al. Plasmablasts as migratory IgG-producing cells in the pathogenesis of neuromyelitis optica. PLoS One 2013;8:e83036.
40. Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis 2015;6:e1792.
41. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol 2014;5:520.
42. Carmi Y, Spitzer MH, Linde IL, Burt BM, Prestwood TR, Perlman N, et al. Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity. Nature 2015;521:99-104.
43. Germain C, Gnjatic S, Tamzalit F, Knockaert S, Remark R, Goc J, et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am J Respir Crit Care Med 2014;189:832-44.
44. Yasuda M, Mizukami M, Hanagiri T, Shigematsu Y, Fukuyama T, Nagata Y, et al.Antigens recognized by IgG derived from tumor-infiltrating B lymphocytes in human lung cancer. Anticancer Res 2006;26:3607-11.
45. Kotlan B, Simsa P, Teillaud JL, Fridman WH, Toth J, McKnight M, et al. Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principle concerning the tumor-infiltrating B lymphocytes. J Immunol 2005;175:2278-85.
46. Hansen MH, Nielsen H, Ditzel HJ. The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci U S A 2001;98:12659-64.
47. Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science 2015;348:74-80.
48. Kanodia S, Da Silva DM, Karamanukyan T, Bogaert L, Fu YX, Kast WM. Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression. Cancer Res 2010;70:3955-64.
49. Maldonado L, Teague JE, Morrow MP, Jotova I, Wu TC, Wang C, et al. Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. Sci Transl Med 2014;6:221ra213.
50. Lutz ER, Wu AA, Bigelow E, Sharma R, Mo G, Soares K, et al.Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res 2014;2:616-31.